NSG
CRSP icon

Nalls Sherbakoff Group’s CRISPR Therapeutics CRSP Stock Holding History

Nalls Sherbakoff Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164 Hold
3
– – ﹤0.01% 370
2026
Q1 		$143 Hold
3
– – ﹤0.01% 406
2025
Q4 		$157 Hold
3
– – ﹤0.01% 435
2025
Q3 		$194 Hold
3
– – ﹤0.01% 420
2025
Q2 		$146 Sell
3
-4
-57% -$155 ﹤0.01% 423
2025
Q1 		$238 Buy
+7
New +$297 ﹤0.01% 424
2023
Q4 		$439 Hold
7
– – ﹤0.01% 420
2023
Q3 		$318 Hold
7
– – ﹤0.01% 442
2023
Q2 		$449 Hold
7
– – ﹤0.01% 457
2023
Q1 		$310 Buy
+7
New +$340 ﹤0.01% 495

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nalls Sherbakoff Group's CRSP Position: Q2 2026 in Review

Nalls Sherbakoff Group held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 3 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #370.

Nalls Sherbakoff Group first reported a position in CRSP in Q1 2023 and has held it in 10 quarters since. The position peaked at $449 in Q2 2023. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Nalls Sherbakoff Group held 3 shares of CRISPR Therapeutics worth $164 as of Q2 2026.
  • Nalls Sherbakoff Group left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q2 2026, its #370 holding.
  • Nalls Sherbakoff Group first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Nalls Sherbakoff Group's CRISPR Therapeutics position peaked at $449 in Q2 2023.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Nalls Sherbakoff Group's 13F filing for Q2 2026, filed 17 Aug 2026.